Articles By Anuja Singh
Does Allarity Therapeutics’ Year-End Strategic Update Signal Renewed Momentum for Stenoparib in Hard-to-Treat Cancers?
Global – December 2025 — Allarity Therapeutics (NASDAQ: ALLR) has outlined key strategic and operational progress in its…
ByDo Wegovy Pricing Pathways in 2026 Signal a Turning Point for Obesity Drug Access…
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited Breakthrough for Motion-Sickness Treatment—and a Turning…
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Will Axsome Therapeutics’ FDA Priority Review of AXS-05 Address a Long-Standing Gap in Alzheimer’s…
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Can Dual Regulatory Approvals Position UltraGreen.ai as a Regional Leader in Fluorescence-Guided and AI-Enabled…
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma,…
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
Does Allarity Therapeutics’ Year-End Strategic Update Signal Renewed Momentum for Stenoparib in Hard-to-Treat Cancers?
Global – December 2025 — Allarity Therapeutics (NASDAQ: ALLR) has outlined key strategic and operational progress in its…
Do Wegovy Pricing Pathways in 2026 Signal a Turning Point for Obesity Drug Access…
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited Breakthrough for Motion-Sickness Treatment—and a Turning…
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Will Axsome Therapeutics’ FDA Priority Review of AXS-05 Address a Long-Standing Gap in Alzheimer’s…
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Can Dual Regulatory Approvals Position UltraGreen.ai as a Regional Leader in Fluorescence-Guided and AI-Enabled…
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma,…
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…